Author | Charles A. Staley, MD

Articles

Commentary (Kooby/Staley): Management of Liver Metastases From Colorectal Cancer

September 01, 2006

The liver is a frequent site of metastatic colorectal disease. Over the past 20 years, improvements in systemic chemotherapy and surgical techniques have improved the survival of patients with hepatic metastases. For 4 decades, fluorouracil and leucovorin were the only drugs available to treat metastatic colorectal cancer, but several new drugs and a variety of novel regimens are now available. Further improvements in results have been seen with the delivery of chemotherapy via the hepatic artery. Surgical resection of liver metastases has been encouraged when possible, and recent advances in surgery such as portal vein embolization, have made liver resection a possibility for more patients. This review considers the timing and sequence of chemotherapy and surgery in this setting, as well as the roles of cryoablation, radiofrequency ablation, and radiation therapy.

Commentary (Staley): Are We Overtreating Some Patients With Rectal Cancer?

December 01, 2004

The authors have presented acomprehensive review of rectalcancer, challenging cliniciansto consider whether some patientsare being overtreated with anymodality including surgical resection,chemotherapy, and/or radiotherapy.Tables 2 and 3 provide an excellentoverview of suggested criteria for decidingbetween polypectomy/observationand radical resection for a cancerconfined to a rectal polyp.

Current Status of Genetic Testing for Colorectal Cancer Susceptibility

February 01, 2002

This article is a comprehensive review of genetic testing for hereditary colorectal cancer detection. There is no longer any doubt that hereditary factors contribute to an increased risk of colon cancer. It remains to be seen how great their contribution is, how best to identify high-risk groups, and how best to care for carriers of the mutated genes. Approximately 25% of colorectal cancers occur in younger individuals or those with a family history of the disease, suggesting a heritable susceptibility.[1]

Commentary (Staley): Management of Hepatocellular Carcinoma

July 01, 2000

As Drs. Nakakura and Choti point out, the incidence of hepatocellular carcinoma (HCC) is rising in many countries including the United States, mainly as the result of a steady increase in hepatitis C infections. Unfortunately, it now seems that the hepatitis C virus is more carcinogenic than the hepatitis B virus, judging from the frequency with which HCC develops among patients with hepatitis C- vs hepatitis B-induced cirrhosis.[1] Numerous studies have demonstrated changes in various oncogenes and tumor suppressor genes, but no consistent sequence of genetic changes has emerged similar to the adenoma-carcinoma sequence in colon cancer.